A carregar...
Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study
BACKGROUND: Melanoma accounts for only 1% of all skin malignant tumors; however, it is the deadliest form of skin cancer. Since 2011, FDA (Food and Drug Administration) approved several novel therapeutic strategies, such as MAPK pathway targeted therapies, to treat cutaneous melanoma patients. Howev...
Na minha lista:
| Publicado no: | J Exp Pharmacol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8163970/ https://ncbi.nlm.nih.gov/pubmed/34079392 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JEP.S297831 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|